Showing posts with label Cell Therapy Commercialization. Show all posts
Showing posts with label Cell Therapy Commercialization. Show all posts

Thursday, July 2, 2015

Celebrate July 4th with 30% Off Select IBC Events!


Take advantage of this special July 4th offer and save 30% off the standard rates to IBC’s Cell Therapy, Bioprocessing & Commercialization, Immuno-Oncology, BioProcess International and Antibody Engineering & Therapeutics when you register by Monday, July 6th.

Cell Therapy, Bioprocessing & Commercialization - Save 30% by using the code XFLASH30 when you register. Visit the event website | Register

Immuno-Oncology - Save 30% by using the code XFLASH30 when you register. Visit the event website | Register

BioProcess International Conference & Exposition - Save 30% by using the code BPIJULY4 when you register.Visit the event website | Register

Antibody Engineering & Therapeutics - Save 30% by using the code AE201530 when you register.Visit the event website | Register


Qualifications, rules and regulations: 
Offer cannot be applied retroactively to confirmed or pending registrations from today's date and prior. 30% discount cannot be combined with any team discounts or other promotions and/or discount offers. Discount is only valid from July 2– July 6, 2015. All registrations are subject to IBC approval. Discount cannot be applied to the Academic/Government Rates.


Share this article with your social network, just click below to share now!


Wednesday, May 27, 2015

Accelerate Your Path from Concept to Product














Learn to how to apply the cost-effective and efficient strategies you need to advance your cell, gene and immunotherapies towards commercial success by attending IBC's Cell Therapy Bioprocessing & Commercialization meeting, held September 30 - October 2, 2015 in Alexandria, VA.

Secure your seat today to attend this year's meeting and learn alongside fellow developers and end-users as you collectively share ideas, solutions and lessons learned to:
  • Accelerate your path from concept to product by applying insightful and relevant strategies from 80+ industry thought-leading speakers across 7 focused tracks >> Download the brochure 
  • Stay at the forefront of innovation by evaluating new technologies and cutting-edge data in the exhibit and poster hall 
  • Jump start collaborations and partnerships through networking luncheons, private exhibit hall tours, evening cocktail receptions, interactive panel discussions and more 

New! All registered attendees gain access to Attendee Connect, the networking tool to make connecting with new customers and partners easier than ever before.

"Cell and gene immunotherapies continue to develop at a rapid pace. IBC continues to grow with this promising field. I will be back in the future!" - Prentice Curry, VP of Quality & Operations, Kite Pharma


Share this article with your social network, just click below to share now!


Friday, August 26, 2011

Innovative Stem Cell Trial in Cleveland

The current multiple sclerosis clinical trial at Cleveland Clinic, University Hospitals Seidman Cancer Center and Case Western Reserve University is working to treat and possible reverse the damage that patients suffering the disease are facing using the patient’s own Mesenchymal stem cells. The goal of the study is to examine if it is possible that stem cells can be a way to strengthen the immune system. his clinical study has already had two patients undergo the procedure and plan to have 24 patients enter the study over the next 2-3 years. According to Cleveland.com, there are clinical studies in Spain, Iran and China examining the same type of procedure.

The scientists collect the patients stem cells, then nurture them in a lab until they are grown and then inject them into the patients arm. The first patient saw his condition ease within a matter of weeks. This video examines the study further:


This fall at the Cell Therapy Commercialization Summit, there will be a full track examining clinical development strategies with speakers from Bioheart, Aldagen, Cytograft Tissue Engineering and more. For more information about the event, download the brochure.


Share this article with your social network, just click below to share now!


Thursday, August 4, 2011

University of Michigan secures adult stem cell lines

According to The Detroit News, The University of Michigan has secured three new adult stem cell lines donated from the skin of adults with bipolar disorder, as well as two more lines of genetically normal cells from a tissue back. These will join the three lines of embryotic cells UM already has to study hemophilia, and Marie-Charcot-Tooth disease and a control line of genetically normal cells. These studies, coming from universities, form the basis for dozens of cell therapies that are moving to the clinic. At the Cell Therapy Commercialization Summit, Brock Reeve, Executive Director of the Harvard Stem Cell Institute, will discuss how cell therapy products are moving from the bench to the boardroom.


Share this article with your social network, just click below to share now!


Tuesday, June 28, 2011

South Korea could be the first country to approve stem cell therapy

The Korea Food and Drug Administration (KFDA) could be the first in the world to approve stem cell therapy as a medicine in the world.  According to the Yonhap News Agency, the therapy would treat acute myocardial infarction.  The stem cells are harvested from the person's body then treated and injected back into the heart. It has passed the safety and validity tests needed for approval.

This September, The Cell Therapy Commercialization Summit will be join by AON Insurance, Argenta Advisors and others to identify how companies can ensure reimbursement for cell therapy treatments long before they are approved by the US FDA. For more about the Cell Therapy Commercialization Summit, download the brochure.

What could approval of a stem cell therapy in South Korea mean for other pending approvals across the world?


Share this article with your social network, just click below to share now!


Tuesday, June 7, 2011

Stem cells have potential for Type I Diabetes

ViaCyte has released news indicating that preliminary studies have shown that mice with Type I Diabetes have been cured when islet cells were injected into the mices' skin to function as pancreatic cells. According to the LA Times, Type I Diabetes is ideal for this type of treatment because it only needs to have one type of cell replaced. By inserting the pancreatic cells into the skin, the cells function as a new pancreas, thereby potentially curing the disease. Funding from the California Institute of Regenerative Medicine made this study possible.

At the Cell Therapy Commercialization Summit, Chad Green, Associate Director for Device Engineering & Manufacturing will be presenting the session, “Identify and Establish Optimal Delivery Systems for Your Cell Therapy Product.” In this session, hear about how Viacyte is pioneering delivery systems for cell therapies such as their Type 1 Diabetes study that has the potential to revolutionize the treatment of diabetes.  Download the brochure to find out more about this session and this year's agenda.


Share this article with your social network, just click below to share now!


Friday, June 3, 2011

Cell Therapy Commercialization Summit Brochure available for download

The Cell Therapy Commercialization Summit is the only multi-stakeholder event that delivers a comprehensive tool kit for taking your cell therapy product from preclinical all the way to commercialization – in only three days.
At the Summit, join over 15 sessions are devoted to the complete clinical development life-cycle, including:

  • → Testing: Use Stem Cell Derived Models for Development Toxicity to Ensure Product Progress
  • → Partnering: Manage Big Pharma Alliances to Ensure Effective Cell Therapy Partnerships
  • → Financing: Manage Costs to Control the Spending Burn and Remain Self-Sustaining
  • → Designing: Choose the Right Design Parameters for Trial Efficiency and Sustainability
  • → Ensuring Quality: Incorporating the Concepts of Pharmaceutical Quality Systems into Cell Therapy Product Development
  • → Manufacturing: Run a Bioprocessing Mechanism that Will Give you a Viable Cost to Goods Model
  • → Storing: Maintain Quality and Maximize Efficiencies in Post-Production Logistics
  • → Delivering: Overcome Cold Chain Inefficiencies to Deliver a Fully Potent, Commercially Viable Product

Download the brochure today.

The Cell Therapy Commercialization Summit is a part of the Clinical Business Expo, the host location and home to 6 exclusive and successful conferences all related to clinical business to deliver the latest technical, operational and scientific approaches for clinical development continuum.  Find out more about CBE, taking place September 19-21, 2011 in Boston, MA here.


Share this article with your social network, just click below to share now!


Tuesday, May 10, 2011

Stem Cell research will continue to be funded by tax dollars

It’s been a rocky road for stem cell researchers in the United States, with both Presidential administrations and the courts going back and forth on whether federal funding can be used to support embryonic stem cell research. According to a recent Reuters report, the latest round went in favor of supporters of the use of ESCs, as an appeals court ruled that the Obama administration can continue to use federal tax dollars for this research.

NIH Director Francis Collins stated, "This is a momentous day -- not only for science, but for the hopes of thousands of patients and their families who are relying on NIH-funded scientists to pursue life-saving discoveries and therapies that could come from stem cell research.”

Executives at the Cell Therapy Commercialization Summit look to rulings such as these to know the barometer for where support is for cell therapy research, and particularly research using ESCs. With this recent victory under their belts, they can continue move forward with their R&D, preclinical and clinical efforts at producing viable cell therapy products, capable of mass commercialization in the coming years.


Share this article with your social network, just click below to share now!


Thursday, May 5, 2011

Save the Date for the 2011 Cell Therapy Commercialization Summit!

The Cell Therapy Commercialization Summit is the only event where business executives, along with clinical operations stakeholders, learn cutting-edge strategies towards production and commercialization of viable therapeutic products, enabling you to turn scientific business challenges into money-making solutions.

Highlights of the Summit include:
Operational Strategies
• Identify Therapeutic Opportunities to Develop the Most Robust Pipelines.
• Manage Big Pharma Alliances To Ensure Effective Partnering of Cell Therapy Platforms
• Implement Your Partnership to Meet Pipeline Development Goals
• Determine What Pipelines Will Attract Investors in an Unstable Economy
• Ensure your Investments Have Enforceable Intellectual Property
• Outsourcing Your Clinical Trials to Minimize Cost and Streamline the Clinical Process
• Maintaining Quality & Maximizing Efficiencies in Post-Production Logistics
• Sail Through the Murky Waters of Reimbursement For Cell Therapies

Business Strategies
• Choose the Right Design Parameters for Trial Efficiency and Sustainability
• Minimize Waste, Maximize Efficiencies, and Speed Up Timelines During the Clinical Trial Transition
• Maintain the Quality of Cell Therapy Products and Ancillary Materials
• Overcome Cold Chain Inefficiencies to Deliver a Fully Potent, Commercially Viable Cell Therapy Product
• Identify and Establish Optimal Delivery Systems for Your Cell Therapy Product
• Running a Bioprocessing Mechanism that Will Give You a Viable Cost to Goods Model

Visit the Cell Therapy Commercialization Summit webpage.

Collocated alongside 5 industry events at the Clinical Business Expo, it is the one cell therapy conference where you will meet 200+ experts, 600+ attendees, 50+ exhibitors and have 10+ hours of incomparable networking time with invested peers in all areas of clinical development. Find out more about the Clinical Business Expo.


Share this article with your social network, just click below to share now!